There were no differences in the expressions of other immune checkpoint genes (CTLA4, TIM3, and TIGIT), except for LAG3 whose expression in ILC2s from tumor tissues was lower than that in PBMCs from HDs or NSCLC patients (Supplementary Figure 3A). This evidence concerns the gene LAG3 and non-small cell lung carcinoma.